Rein Therapeutics, Inc.
RNTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001420565
No open-market purchases or sales by Rein Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $42.5M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +14 vs. previous quarter
- 59
- 13F valueReported value at the end of Q2 2026
- $42.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RNTX, Q2 2026
No superinvestor reported holding RNTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Rein Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 (view filing) | May 21-27 | 7 daysLate | Von Rickenbach Josef HDirector | PPurchaseCommon stock , $0.001 par value | +47.1K | $1.06 | +$49.7K | +304.5%62.5K after | 4 lots |
| May 13, 2026 (view filing) | Apr 30 | 13 daysLate | Windsor James BrianSee Remarks | PPurchaseCommon stock , $0.001 par value | +25.0K | $1.00 | +$25.0K | +1,221.9%27.0K after | |
| Nov 18, 2025 (view filing)5:30 PM ET | Nov 14 | 4 days | Voss Capital, LP and 4 others10% Owner | PPurchaseCommon Stock, $0.001 par value | +104.2K | $1.22 | +$127.6K | +12.7%926.4K after | |
| Oct 28, 2025 (view filing)6:45 PM ET | Oct 24-28 | 4 days | Voss Capital, LP and 4 others10% Owner | PPurchaseCommon Stock, $0.001 par value | +306.1K | $1.38 | +$423.5K | +157.8%500.0K after | 4 lots |
| Dec 9, 2024 (view filing) | Dec 5 | 4 days | Windsor James BrianPresident and CEO | PPurchase | +400 | $2.24 | +$897.61 | New position161 after | 2 lots |
| Jun 17, 2024 (view filing) | Jun 14-17 | 3 days | University Of Texas/Texas Am Investment Management Co10% Owner | SSale | −6.61K | $3.26 | −$21.6K | −0.4%1.75M after | 2 lots |
| Jun 12, 2024 (view filing) | Jun 10-12 | 2 days | University Of Texas/Texas Am Investment Management Co10% Owner | SSale | −24.7K | $3.27 | −$80.7K | −1.4%1.75M after | 5 lots |
| Jun 7, 2024 (view filing) | Jun 5-7 | 2 days | University Of Texas/Texas Am Investment Management Co10% Owner | SSale | −12.3K | $3.29 | −$40.5K | −0.7%1.78M after | 5 lots |
| May 14, 2024 (view filing) | May 1 | 13 days | University Of Texas/Texas Am Investment Management Co10% Owner | SSale | −20.3K | $4.21 | −$85.5K | −1.1%1.79M after | Amended16 lots |
| Dec 18, 2023 (view filing) | Dec 15 | 3 days | Windsor James BrianPresident and COO | PPurchase | +225 | $3.37 | +$758.25 | New position225 after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Rein Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Voss Capital, LLC | 5,261,921 | $5.47M | 0.27% | +873,559+19.9% | Added |
| Cable Car Capital LLC | 5,195,000 | $5.40M | 0.12% | +4,775,000+1,136.9% | Added |
| ADAR1 Capital Management, LLC | 4,500,000 | $4.68M | 0.22% | +4,500,000 | New |
| Vanguard Capital Management LLC | 3,377,910 | $3.51M | 0.00% | +2,379,389+238.3% | Added |
| BIOS Capital Management, LP | 2,982,375 | $3.10M | 7.44% | +1,000,000+50.4% | Added |
| Ikarian Capital, LLC | 2,950,000 | $3.07M | 0.50% | +2,950,000 | New |
| Great Point Partners LLC | 2,575,000 | $2.68M | 0.63% | +2,575,000 | New |
| Citadel Advisors LLC | 2,438,711 | $2.54M | 0.00% | +2,438,711 | New |
| Velan Capital Investment Management LP | 1,700,000 | $1.77M | 1.08% | +1,700,000 | New |
| Senvest Management, LLC | 1,230,895 | $1.28M | 0.04% | +1,000,000+433.1% | Added |